Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.86 |
| ▸ | NTSR1 | P30989 | 7/20 | 0.77 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.77 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.77 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.74 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dynorphin A (1-11) SCHEMBL30132402 | 1.00 | OPRD1 (0.86) | OPRD1NTSR1OPRM1OPRK1NTSR2 | |
| SCHEMBL29878209 | 0.99 | OPRD1 (0.85) | OPRD1NTSR1OPRM1OPRK1NTSR2 | |
| SCHEMBL29648931 | 0.97 | OPRD1 (0.90) | OPRD1NTSR1OPRM1OPRK1NTSR2 | |
| SCHEMBL31009049 | 0.97 | OPRD1 (0.88) | OPRD1NTSR1OPRM1OPRK1NTSR2 | |
| SCHEMBL29386868 | 0.94 | OPRD1 (0.82) | OPRD1NTSR1OPRM1OPRK1 | |
| SCHEMBL31197421 | 0.92 | OPRD1 (0.77) | OPRD1NTSR1OPRM1OPRK1NTSR2 | |
| SCHEMBL11191224 | 0.92 | OPRD1 (0.75) | OPRD1NTSR1OPRM1OPRK1NTSR2 | |
| Analog Of Dynorphin A SCHEMBL27861937 | 0.92 | OPRD1 (0.75) | OPRD1NTSR1OPRM1OPRK1NTSR2 | |
| Dynorphin A (1-17) SCHEMBL29599476 | 0.89 | OPRD1 (0.70) | OPRD1NTSR1OPRM1OPRK1NTSR2 | |
| Dynorphin A (1-17) SCHEMBL29358748 | 0.89 | OPRD1 (0.70) | OPRD1NTSR1OPRM1OPRK1NTSR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3472196-B1 | NEUROPEPTIDE-EXPRESSING VECTORS AND METHODS FOR THE TREATMENT OF EPILEPSY | UNIV BERLIN CHARITE (DE) | 2026-03-18 | — | — | EP | claimed |
| US-20240269230-A1 | CYCLOTIDES IN COMBINATION WITH KAPPA OPIOID RECEPTOR LIGANDS FOR MS THERAPY | MEDIZINISCHE UNIVERSITAT WIEN (AT) | 2024-08-15 | — | — | US | claimed |
| CN-115697371-A | Macrocyclic oligopeptides in combination with kappa opioid receptor ligands for MS therapy | 维也纳医科大学 | 2023-02-03 | — | — | CN | claimed |
| EP-4121085-A1 | CYCLOTIDES IN COMBINATION WITH KAPPA OPIOID RECEPTOR LIGANDS FOR MS THERAPY | Medizinische Universität Wien (AT) | 2023-01-25 | — | — | EP | claimed |
| EP-4731246-A2 | ALBUMIN BOUND MACROMOLECULE TRI-AGONIST ACTIVATING GLP-1/GIP/GLUCAGON RECEPTORS | AlbuNext, LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-3472196-B1 | NEUROPEPTIDE-EXPRESSING VECTORS AND METHODS FOR THE TREATMENT OF EPILEPSY | UNIV BERLIN CHARITE (DE) | 2026-03-18 | — | — | EP | disclosed |
| US-12576141-B2 | Albumin bound macromolecule tri-agonist activating GLP-1/GIP/glucagon receptors | AlbuNext, LLC (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | UNIV LELAND STANFORD JUNIOR (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260027128-A1 | ORALLY INHALED AND NASAL BENZODIAZEPINES | PAION UK LTD (GB) | 2026-01-29 | — | — | US | disclosed |
| US-20250368645-A1 | BETA CARBOLINE ANALOGUES AS SELECTIVE AND BIASED KAPPA OPIOID RECEPTORS AGONISTS FOR TREATING VARIOUS ASSOCIATED PATHOPHYSIOLOGICAL CONDITIONS | COUNCIL SCIENT IND RES (IN) | 2025-12-04 | — | — | US | disclosed |
| US-20250360144-A1 | DOSING REGIMEN FOR SEDATION WITH CNS 7056 (REMIMAZOLAM) | PAION UK LTD. (GB) | 2025-11-27 | — | — | US | disclosed |
| US-20250354986-A1 | AFFINITY ENCODED OSCILLATOR ARRAYS, METHODS, AND RELATED ASPECTS FOR MEASURING MOLECULAR BINDING KINETICS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2022136486-A1 | CONOLIDINE ANALOGUES AS SELECTIVE ACKR3 MODULATORS FOR THE TREATMENT OF CANCER AND CARDIOVASCULAR DISEASES | LUXEMBOURG INSTITUTE OF HEALTH (LIH) (LU) | 2022-06-30 | — | — | WO | disclosed |
| US-20220176095-A1 | MICRONEEDLE HAVING STRUCTURE OF THREE OR MORE LAYERS, AND METHOD FOR MANUFACTURING SAME | FEROKA INC. (KR) | 2022-06-09 | — | — | US | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| US-20220098283-A1 | ACE2- and TMPRSS2-Targeted Compositions and Methods for Treating COVID-19 | MADDON ADVISORS LLC (US) | 2022-03-31 | — | — | US | disclosed |
| EP-3962510-A1 | NOVEL SELECTIVE ACKR3 MODULATORS AND USES THEREOF | Luxembourg Institute Of Health (LIH) (LU) | 2022-03-09 | — | — | EP | disclosed |
| US-20220056153-A1 | ACE2-Targeted Compositions and Methods for Treating COVID-19 | MADDON ADVISORS LLC (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220056154-A1 | Bispecific Antibody Compositions and Methods for Treating COVID-19 | MADDON ADVISORS LLC (US) | 2022-02-24 | — | — | US | disclosed |
| US-11246873-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | OPRD1 2716/4885NTSR1 1286/4885OPRM1 1737/4885 |
| US-12576141-B2 | Albumin bound macromolecule tri-agonist activating GLP-1/GIP/glucagon receptors | GLP1R, GCGR, GIPR | OPRD1 323/4885NTSR1 102/4885OPRM1 298/4885 |
| US-20250360144-A1 | DOSING REGIMEN FOR SEDATION WITH CNS 7056 (REMIMAZOLAM) | OPRM1, OPRK1, GABRA5 | OPRD1 4/4885NTSR1 254/4885OPRM1 1/4885 |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | ADAR, ZFR, SLIRP | OPRD1 2320/4885NTSR1 689/4885OPRM1 1894/4885 |
| US-20250368645-A1 | BETA CARBOLINE ANALOGUES AS SELECTIVE AND BIASED KAPPA OPIOID RECEPTORS AGONISTS FOR TREATING VARIOUS ASSOCIATED PATHOPHYSIOLOGICAL CONDITIONS | OPRK1, OPRD1, OPRM1 | OPRD1 2/4885NTSR1 48/4885OPRM1 3/4885 |
| US-20260027128-A1 | ORALLY INHALED AND NASAL BENZODIAZEPINES | GABRA2, GABRP, GABRE | OPRD1 28/4885NTSR1 792/4885OPRM1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.